Losartan: Discovery, Development, Safety and Pharmacovigilance
Losartan is an orally active angiotensin II type 1 (AT1) receptor antagonist. Its introduction established a therapeutic alternative to inhibiting angiotensin-converting enzyme (ACE): rather than suppressing one major route by which angiotensin II is formed, losartan prevents angiotensin II from activating its principal cardiovascular and renal effector receptor. It is an established antihypertensive, but the clinical and safety history is more extensive than blood-pressure reduction alone. Trials in hypertensive left ventricular hypertrophy and type 2 diabetic nephropathy, differences among regional authorisations, fetal toxicity, altered kidney function, hyperkalaemia and manufacturing-impurity recalls have each shaped its use and oversight. [1–4]
This article concerns the international nonproprietary name losartan, generally supplied as losartan potassium. Cozaar is an originator brand name used here only to identify relevant regulatory and historical records; findings for a specific brand, formulation or region must not automatically be generalized to every authorised product.
- Losartan: Discovery, Development, Safety and Pharmacovigilance
- Scientific origins and discovery
- From antihypertensive development to product authorisation
- Clinical evidence and interpretation
- Pharmacology, administration and interactions
- Safety profile and special populations
- Manufacturing quality and nitrosamine contamination
- EU pharmacovigilance implementation
- Synthesis and key takeaways
- References
- Regulatory Note
Scientific origins and discovery
The renin–angiotensin system as a drug target
Renin converts angiotensinogen to angiotensin I. ACE then generates angiotensin II, which activates receptors involved in vasoconstriction, aldosterone release, sodium retention and cardiovascular and renal tissue responses. ACE inhibitors were already clinically established, but they also alter bradykinin metabolism and do not prevent angiotensin II arising from every non-ACE pathway. This furnished a mechanistic rationale for a drug acting directly at the angiotensin II receptor. [1]
Early angiotensin II antagonists were peptides, limiting their development as convenient oral medicines. Medicinal chemistry programmes therefore sought selective, orally active non-peptide compounds. DuPont researchers developed the biphenyltetrazole chemical lineage that produced losartan. Timmermans and colleagues described three scientific contributions: identifying a clinically useful molecule, using it to distinguish AT1 receptor biology and using receptor blockade to investigate angiotensin II physiology. The DuPont–Merck development history belongs to this discovery era; later organisational or brand ownership should not be mistaken for the laboratory origin of the molecule. [1]
Mechanism and active metabolite
Losartan selectively antagonises the AT1 receptor without directly inhibiting ACE. Blockade reduces angiotensin II-mediated vasoconstriction and aldosterone effects, but does not switch off all renin–angiotensin physiology. An active carboxylic-acid metabolite contributes substantially to pharmacological activity; this is relevant when interpreting hepatic metabolism and drug interactions. Individual blood-pressure responses depend on salt balance, kidney function, concomitant therapy and other clinical variables. [2,3]
The mechanistic distinction from ACE inhibitors helps explain why cough related to bradykinin accumulation is less characteristic of losartan. It does not mean losartan is free of angioedema risk, hypotension, renal haemodynamic effects or fetal toxicity. A mechanism-based safety interpretation must distinguish differences between classes from hazards shared by agents that act on the renin–angiotensin system.
From antihypertensive development to product authorisation
Losartan reached clinical practice during the 1990s; the current US Cozaar label records initial US approval in 1995. Its early development established dose-dependent blood-pressure lowering and tolerability in hypertension. Subsequent trials evaluated clinical outcomes beyond the surrogate endpoint of office blood pressure. Losartan became available in multiple dosage strengths and later as part of combination regimens, including hydrochlorothiazide-containing products. Such combinations have their own labelling and interaction considerations; their efficacy or sales cannot be counted as monotherapy outcomes. [2]
The European regulatory history illustrates an important distinction. Losartan-containing Cozaar presentations were authorised through national procedures; a European Medicines Agency Article 30 referral sought harmonisation of nationally authorised product information. The EMA record describes a referral begun in 2007 addressing hypertension, renal disease progression, stroke-risk reduction and particular chronic-heart-failure circumstances. A harmonisation referral does not imply that losartan was newly centrally authorised or that every indication has identical wording worldwide. [4]
For contemporary practice, the authorised Summary of Product Characteristics (SmPC) in the relevant EU Member State governs product-specific indications, contraindications, dosing and precautions. The current US label is useful comparative evidence but cannot substitute for the applicable EU SmPC. [2–4]
Clinical evidence and interpretation
Renal protection: the RENAAL trial
RENAAL was a randomised, double-blind study in 1,513 patients with type 2 diabetes and nephropathy. Losartan 50–100 mg daily or placebo was added to conventional antihypertensive treatment over a mean follow-up of 3.4 years. The composite primary endpoint comprised doubling of serum creatinine, end-stage renal disease or death. The endpoint occurred in 327 losartan recipients versus 359 placebo recipients; the published relative risk reduction was 16% (P=0.02). Doubling of serum creatinine and end-stage renal disease were reduced, while the trial did not establish a reduction in all-cause death. [5]
The trial made diabetic kidney disease a central component of losartan's evidence base. Nevertheless, the renal endpoint and studied population matter: improvement in proteinuria or a renal composite is not proof of a mortality advantage, nor should the trial be extrapolated indiscriminately to all forms of chronic kidney disease. The US product indication specifies type 2 diabetic nephropathy in patients with hypertension, elevated creatinine and proteinuria, while the EU SmPC wording must be checked for each authorised product. [2–5]
Hypertension with left ventricular hypertrophy: LIFE
The LIFE programme compared losartan-based and atenolol-based regimens in people with hypertension and electrocardiographic left ventricular hypertrophy. The outcomes supported stroke-risk reduction in the studied population and informed product information. Because this was a treatment-strategy comparison, the inference concerns the randomised regimens and population, not an assertion that losartan is superior to every other drug at equivalent blood-pressure control. The US label specifically qualifies the stroke-risk indication by noting evidence that the benefit does not apply to Black patients in the relevant subgroup analysis. That is a population-specific product-labelling statement, not a biological rule about individuals. [2]
Heart failure and boundaries of the evidence
Losartan also underwent comparative research in heart failure, including studies involving captopril. Comparisons with ACE inhibitors did not establish a universal superiority of losartan for survival. Clinical decisions must therefore reflect the studied setting, the prevailing evidence for other guideline-directed therapies and regional indications. Where national EU SmPCs include chronic heart failure under specified circumstances, those restrictions are part of the indication, not merely optional prescribing suggestions. [3,4]
| Evidence domain | What the evidence supports | Important limitation |
|---|---|---|
| Hypertension | Reduction in blood pressure | Blood-pressure response does not by itself establish every organ-protection claim |
| Diabetic nephropathy (RENAAL) | Reduced composite renal progression outcome | No demonstrated overall survival benefit in that trial |
| Hypertension with LV hypertrophy (LIFE) | Benefit on stroke-related clinical outcomes for studied regimen/population | Population and comparator matter; US label has a subgroup qualification |
| Heart failure | Investigated as an alternative RAAS strategy | Do not infer superior mortality benefit over established alternatives |
Pharmacology, administration and interactions
Losartan is administered orally; the dosage and adjustment instructions depend on indication, age, volume status, hepatic function and applicable product. The US reference label includes tablets of 25, 50 and 100 mg, but formulation availability varies across markets. An active metabolite and hepatic metabolism contribute to variability in exposure and response. [2,3]
Combining losartan with potassium supplements, potassium-containing salt substitutes or potassium-sparing treatments can increase hyperkalaemia risk. Non-steroidal anti-inflammatory drugs may compromise renal function and blunt antihypertensive efficacy, particularly in susceptible or volume-depleted patients. Additional renin–angiotensin system blockade with ACE inhibitors or aliskiren increases the potential for hypotension, hyperkalaemia and kidney injury; the precise contraindications and precautions are product- and jurisdiction-specific. In the US, coadministration with aliskiren in people with diabetes is contraindicated. [2,3]
These interactions are not adequately characterised by a simplistic 'drug–drug interaction present' flag. A medically meaningful case assessment needs the exposure sequence, indication, baseline kidney function, fluid losses, serum potassium, concomitant drugs and the clinical response to treatment changes.
Safety profile and special populations
Fetal toxicity and pregnancy
Medicines acting directly on the renin–angiotensin system can damage fetal renal development and cause serious fetal harm. The US losartan label carries a boxed warning for fetal toxicity and directs discontinuation as soon as pregnancy is detected. The UK Cozaar SmPC states that use is not recommended in the first trimester and is contraindicated during the second and third trimesters; patients planning pregnancy should ordinarily transition to an appropriate alternative. These are different jurisdictional formulations of a shared clinically serious risk, and neither should be silently paraphrased into the other's legal wording. [2,3]
Pharmacovigilance assessment of pregnancy exposure should collect gestational timing, formulation, dose, exposure duration, other medicines, maternal conditions, fetal imaging and neonatal renal outcomes where available. The absence of an adverse fetal outcome in one reported pregnancy cannot remove the established warning. Nor should a spontaneous report without a clear outcome be treated as a confirmed congenital anomaly.
Renal haemodynamics, electrolytes and blood pressure
By reducing angiotensin II effects on the kidney, losartan can alter glomerular perfusion pressure. Clinically important increases in creatinine or acute kidney injury may occur in patients with renal-artery stenosis, low circulating volume or concurrent medicines that compromise renal autoregulation. Hyperkalaemia, symptomatic hypotension and syncope are additional recognised risks. In clinical practice, renal function, potassium and blood pressure are assessed in accordance with the indication, comorbidities and applicable product information. [2,3]
A rise in serum creatinine after treatment begins requires interpretation rather than reflex classification as either expected or harmful. Magnitude, time course, baseline impairment, competing causes and reversibility are needed to evaluate the event. Similarly, hyperkalaemia may reflect the joint effects of losartan, kidney disease, potassium supplementation and interacting therapies.
Hypersensitivity and other events
Angioedema and hypersensitivity events warrant prompt clinical assessment and accurate drug attribution. Losartan has a different relationship to bradykinin from ACE inhibitors, but prior ACE-inhibitor-associated angioedema does not make every subsequent event unrelated to losartan. Case narratives should establish airway involvement, timing, differential diagnoses and concomitant exposures. The frequency terminology in the relevant current SmPC should be used rather than estimating incidence from spontaneous-report counts. [2,3]
Manufacturing quality and nitrosamine contamination
A separate safety chapter began in 2018 when regulators identified nitrosamine impurities in some angiotensin II receptor blocker products. Specific lots of losartan-containing medicines were among those recalled. FDA investigations identified manufacturing process conditions and reused solvents as possible contributors to nitrosamine formation, with compounds including NDMA, NDEA and NMBA implicated in the wider ARB investigation. Not every losartan product or batch was contaminated; a recall is batch-, manufacturer- and market-specific. [6,7]
This distinction is fundamental for pharmacovigilance and quality governance. A pharmacologically mediated adverse reaction applies to exposure to the active substance in a susceptible patient. An impurity-related concern may depend on a particular active-ingredient manufacturing route, batch, duration of exposure and impurity level. The source and magnitude of any potential cancer risk must not be invented from the mere fact of a recall. FDA advised against abrupt discontinuation before replacement arrangements because sudden interruption of needed treatment also carries risk. [6,7]
Effective governance requires exchange between pharmacovigilance, manufacturing quality, regulatory affairs and supply-chain teams. Impurity assessments, validated analytical methods, distribution and recall traceability, patient communication, treatment continuity and any medically relevant exposure complaints should be reconciled without conflating quality defects with observed adverse drug reactions.
EU pharmacovigilance implementation
EU pharmacovigilance obligations derive from the applicable medicines legislation and implementing rules; EMA Good Pharmacovigilance Practices (GVP) describe operational and scientific expectations. For losartan, activities include appropriately identifying and reporting suspected adverse reactions, signal management, aggregate benefit–risk evaluation and maintaining product information and risk-management arrangements as applicable. GVP guidance should not be represented as a new losartan-specific legal obligation. [8]
Routine surveillance should preserve the distinction between established labelled reactions and emerging information. Signals involving fetal exposure, renal injury, severe hyperkalaemia, angioedema, medication errors or unexpected outcomes require clinical case validation, duplicate management and appropriate evaluation against exposure patterns and background disease. Manufacturing defects additionally require defined interfaces with quality and recall management. [2,3,6–8]
Evidence required to evaluate a suspected case
| Question | Useful evidence | Why it matters |
|---|---|---|
| Was the patient exposed? | INN, brand, strength, formulation, dates, batch if relevant | Identifies product and chronology |
| Is the outcome medically characterised? | Diagnoses, laboratory values, imaging, intervention and outcome | Distinguishes meaningful events from vague symptoms |
| What alternative causes exist? | Dehydration, kidney disease, infection, pregnancy, concurrent treatments | Supports causality assessment |
| Was a specific quality issue implicated? | Lot, manufacturer, recall notice, available analytical findings | Differentiates batch impurity from pharmacological toxicity |
| What changed after intervention? | Withdrawal, dose alteration, alternative therapy, follow-up laboratory results | Clarifies clinical evolution without proving causation alone |
Illustrative inspection scenario
Suppose a marketing authorisation holder receives reports of hyperkalaemia, several involving a potassium-sparing diuretic and chronic kidney disease. An inspector evaluating the system's effectiveness could ask whether the cases were processed to applicable timelines, accurately coded, linked to interacting therapies, incorporated into ongoing signal assessment and reflected in any necessary risk-minimisation evaluation. This is a hypothetical inspection question, not a reported regulatory finding. Audit trails should connect the original report, medical assessment, signal decision and governance action.
For a nitrosamine-related complaint, a separate evidence trail should demonstrate the link between the batch, laboratory investigation, distribution traceability, recall decision and communication to affected stakeholders. Any associated clinical adverse-reaction reports require their own pharmacovigilance assessment; documenting a manufacturing defect does not substitute for it.
Synthesis and key takeaways
Losartan introduced practical AT1-selective blockade and subsequently acquired an evidence base spanning blood-pressure control, stroke prevention in a defined hypertensive population and renal progression in type 2 diabetic nephropathy. Interpretation requires careful attention to the actual trial endpoints and populations. Its major routine risks follow from the physiology of renin–angiotensin blockade, particularly pregnancy toxicity, altered renal function, hyperkalaemia and hypotension. The ARB nitrosamine episode added a distinct quality-linked exposure concern. A robust pharmacovigilance system recognises both risk types, applies the current regional product information and retains traceable evidence for clinical and regulatory decisions.
References
- Timmermans PBMWM, Duncia JV, Carini DJ, et al. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995;9 Suppl 5:S3–S18. PMID:8583479. https://pubmed.ncbi.nlm.nih.gov/8583479/
- US National Library of Medicine. DailyMed: Cozaar (losartan potassium), official US prescribing information, reviewed 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39
- Electronic Medicines Compendium. Cozaar 50 mg film-coated tablets, UK Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/7799/smpc
- European Medicines Agency. Cozaar and associated names, Article 30 referral. https://www.ema.europa.eu/en/medicines/human/referrals/cozaar
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. https://doi.org/10.1056/NEJMoa011161
- US Food and Drug Administration. Recalls of angiotensin II receptor blockers including valsartan, losartan and irbesartan. https://www.fda.gov/drugs/drug-safety-and-availability/recalls-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan
- US Food and Drug Administration. Investigation of NMBA in certain losartan lots and associated recall. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632425.htm
- European Medicines Agency. Good pharmacovigilance practices, including Module IX (signal management). https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
Regulatory Note
This article distinguishes historical scientific evidence, current product-specific labelling and EU pharmacovigilance guidance. UK and US product information are used as clearly labelled jurisdictional examples; neither replaces the current authorised SmPC of a particular EU product. Regulatory details and market-specific recalls should be rechecked at the time of a clinical or regulatory decision. The discussion is educational and is not individual prescribing advice.